| Literature DB >> 32510771 |
Letizia Corinna Morlacchi1,2, Valeria Rossetti1,2, Lorenzo Gigli3, Francesco Amati1,2, Lorenzo Rosso2,4, Stefano Aliberti1,2, Mario Nosotti2,4, Francesco Blasi1,2.
Abstract
Limited data are currently available regarding the course of COVID-19 in lung and solid organ transplant recipients. We hereby present four cases of SARS-CoV-2 pneumonia in lung transplant recipients from our center, set in Milan, Italy. We reduced immunosuppressive regimen in all these patients, typically holding the antiproliferative agent and augmenting steroids; everybody received hydroxychloroquine, initial empiric antibiotic treatment with piperacillin/tazobactam, and high-dose low molecular weight heparin. Clinical course seemed favorable in three of our patients, but one of them deteriorated after 10 days of hospitalization, probably due to an acute form of graft dysfunction triggered both by COVID-19 and a nosocomial bacterial infection, and eventually died. Although short-term prognosis could be considered benign in the majority of our patients, we should carefully monitor these individuals in order to detect early sign of clinical deterioration and graft dysfunction in the next few months.Entities:
Year: 2020 PMID: 32510771 DOI: 10.1111/tid.13356
Source DB: PubMed Journal: Transpl Infect Dis ISSN: 1398-2273 Impact factor: 2.228